None listed
Conditions
Interventions
Dietary Supplement : Subjects will be randomized to receive Ginseng Berry extract tablet 60 mg or placebo. Subjects will orally self-administer Crataegus pinnatifida Bunge extract capsule 30 mg or pl
Sponsors
OKCHUNDANG
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Males and females 45 =age = 65 2. Those with elementary school or higher education 3. Subjects whose MQ(Memory Quotient) score in Rey-Kim memory test is 70 or more, but less than 120. 4. Subjects who after listening carefully and fully understanding this clinical trial, has decided to participate voluntarily and has agreed in writing to observe the cautions. 5. Subjects who are possible to follow up during the trial period. 6. Subjects whose depression or anxiety subscale score in HADS(Hopital Anxiety and Depression Scale) is less than 8. 7. Subjects who doesn’t meet the exclusion criteria
Exclusion criteria
Exclusion criteria: 1. Subjects with physical diseases which can affect memory such as neurodegenerative diseases like dementisa, Parkinson disease, traumatic brain injury, stroke. 2. Subjects who have taken any medicines or dietary supplements which can affect memory within 4 weeks. 3. Subjects who have allergic reaction or hypersensitive reaction to experimental supplement. 4. Subjects who have hepatoma, liver cirrhosis, chronic renal failure, congestive heart failure. 5. Subjects who have been taking antihistaminic agent, nonsteroidal antiinflammatory drug, steroid, antibiotics, decongestant. 6. Subjects who have been taking any medicine to treat hyperthyroidism or hypothyroidism within 1 year.(Subjects who investigators decided to be possible to participate to this trial can be involved.) 7. Subjects who have severe migraine, thromboembolism, cerebrovascular disease, myocardial infarction, unstable angina pectoris, or PTCA within 1 year. 8. Subjects who have mental disorders like depression, anxiety disorders, or been taking any antidepressants, antipsychotics agents. 9. Subjects who have uncontrolled diabetes mellitus. (FBT = 80mg/dL or Subjects who started new hypoglycemic agents withing the last 3 months) 10. Subjects who have history of drug or alcohol dependency or abuse. 11. ALT(Alanine transaminase) or AST(Aspartate transaminase) > 2.5 times compared to the normal upper limit in research institute. 12. Creatinine > 2.5 times compared to the normal upper limit in research institute. 13. Subjects who participated in another clinical study in the last 30 days or plan to participate in another clinical study. 14. Subjects who are pregnancy, breast feeding, or females of childbearing potential who are not practicing acceptable pregnancy prevention methods. 15. Subjects who are institutionalized in group facilities like social welfare organs. 16. Subjects who have difficulty of communication or writing due to visual, auditory, physical impairment. 17. Subjects who are not appropriate by investigator’s decision.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rey-Kim memory test MQ(Memory Quotient) | — |
Secondary
| Measure | Time frame |
|---|---|
| Rey-Kim memory test K-AVLT(the Korean-Auditory Verbal. Learning Test) learning curve, Memory retention, retrieval efficiency;Rey-Kim memory test K-CFT(the Korean-Complex Figure Test);The change of digit span assessment score;ß-amyloid protein | — |
Countries
Korea, Republic of
Contacts
Public ContactHANA LEE
Pusan National University Korean Medicine Hospital
Outcome results
None listed